View Older Stories View More Recent Stories
-
RFK Jr.'s HHS to Stop Recommending Routine Covid Shots for Kids, Pregnant Women -- WSJ
-
BioNTech (BNTX) PT Lowered to $134 at H.C. Wainwright
-
BioNTech (BNTX) PT Lowered to $140 at Citi
-
BioNTech SE (BNTX) Tops Q1 EPS by 27c
-
BioNTech SE (BNTX) Hits Low, Down 8%, Summit Therapeutics (SMMT) Falls 18.5%
-
BioNTech (BNTX) PT Lowered to $145 at H.C. Wainwright
-
Truist: 'Expect Some Pressure On Dr. Marks' Resignation'
-
CureVac N.V. (CVAC) Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
-
CureVac N.V. (CVAC) Gets Positive Validity Decision In Suit Vs BioNTech (BNTX)
-
Berenberg Reiterates Buy Rating on BioNTech (BNTX)
-
BioNTech (BNTX) PT Lowered to $151 at Truist Securities
-
BioNTech (BNTX) PT Raised to $143 at BMO Capital
-
Jefferies Reiterates Buy Rating on BioNTech (BNTX)
-
BioNTech SE (BNTX) Reports Q4 EPS of EUR1.08; offers guidance
-
CDC Plans Large Study Into Potential Connections Between Vaccines and Autism - Reuters
-
BioNTech SE (BNTX) call put ratio 1 calls to 3.6 puts with a focus on March puts
-
BioNTech SE (BNTX) says FDA placed clinical hold on IND and related Phase I/IIa clinical trial of BNT165e
-
Clear Street Starts BioNTech (BNTX) at Buy
-
Clorox (CLX) gains 2.7% on new virus concerns
-
Moderna (MRNA) Strength tied to Speculation About New Coronavirus
-
RFK, Jr. said confirmed
-
Moderna (MRNA) on Watch as RFK Jr. Clears Senate Committee, Will Get Full Vote To Head HHS
-
Moderna stock rises following RFK Jr's comments
-
Truist Securities Starts BioNTech (BNTX) at Buy
-
BioNTech SE (BNTX): FDA has lifted partial clinical hold on PRESERVE-003 trial
-
BMO Capital Reiterates Outperform Rating on BioNTech (BNTX)
-
TD Cowen Reiterates Hold Rating on BioNTech (BNTX)
-
Evercore ISI Upgrades BioNTech (BNTX) to Outperform
-
Berenberg Starts BioNTech (BNTX) at Buy
-
Increasing unusual put option volume: ZI AAOI OKLO DJX IYR BNTX
-
Moderna (MRNA), Others on Watch Following Report Trump Expected to Select Robert F. Kennedy Jr. to lead HHS
-
BioNTech (BNTX) PT Raised to $121 at Leerink Partners
-
Goldman Sachs Upgrades BioNTech (BNTX) to Buy
-
BioNTech (BNTX) PT Lowered to $122 at TD Cowen
-
BioNTech (BNTX) PT Raised to $126 at BMO Capital
-
BioNTech SE (BNTX) Tops Q3 EPS by 236c
-
BofA Securities Reiterates Buy Rating on BioNTech (BNTX)
-
BioNTech (BNTX) PT Raised to $132 at TD Cowen
-
BioNTech SE (BNTX): FDA has placed partial clinical hold on two-stage, open-label, randomized Phase 3 trial, PRESERVE-003
-
UK MHRA: approved an adapted Pfizer (PFE) /BioNTech (BNTX) Covid-19 vaccine (comirnaty) that targets the KP.2 Covid-19 subvariant for adults
-
BioNTech (BNTX) PT Raised to $150 at H.C. Wainwright
-
BioNTech (BNTX) PT Raised to $136 at HSBC
-
TD Cowen Reiterates Hold Rating on BioNTech (BNTX)
-
BioNTech SE (BNTX) Highlights AI Capabilities and R&D Use Cases
-
Pfizer (PFE), BioNTech (BNTX) gain positive CHMP opinon on Omicron KP.2-adapted COVID-19 vaccine in EU
-
BioNTech SE (BNTX) September 115 puts, December 110 puts active
-
Jefferies Upgrades BioNTech (BNTX) to Buy
-
TD Cowen Reiterates Hold Rating on BioNTech (BNTX)
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
JPMorgan Upgrades BioNTech (BNTX) to Neutral

